A new study suggests that a vitamin D analog could help disrupt the protective barriers of pancreatic cancer, potentially increasing the effectiveness of chemotherapy and immune therapies. The research, based on a small clinical trial, indicates that patients with tumors rich in vitamin D receptors showed positive responses.
The trial focused on patients whose tumors had high levels of the vitamin D receptor, a key factor in the study's observed outcomes.